No controlled study has tested mescaline at microdose amounts in people, and none is registered anywhere. How the compound behaves in the body is well described; whether it helps is not. Costs are concrete: nausea, raised blood pressure, disturbed sleep, weaker concentration, serious criminal exposure, and a supply drawing on a threatened cactus or an unregulated market. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Seated blood pressure | 105–120 / 65–78 mmHg | Detects the documented blood-pressure rise and defines the safety margin before dosing |
| Resting heart rate | 50–65 beats per minute | Baseline for the documented heart-rate effect; a rising trend across a protocol signals cumulative sympathetic load |
| 12-lead electrocardiogram with QTc interval | QTc < 440 ms (men), < 450 ms (women) | Screens for pre-existing conduction abnormality that would amplify the consequence of the cardiovascular effect |
| Creatinine and estimated glomerular filtration rate | eGFR > 90 mL/min/1.73 m² | Roughly half of a dose is cleared unchanged by the kidneys, so filtration directly sets exposure |
| Alanine and aspartate aminotransferase | ALT 10–26 U/L, AST 10–26 U/L | Liver enzymes that flag hepatic stress; supervised full-dose studies found no change, providing a reference expectation |
| Complete blood count | Within reference, ferritin 50–150 ng/mL | Supervised mescaline studies documented no change in blood cell counts, so any change points elsewhere |
| High-sensitivity C-reactive protein | < 0.5 mg/L | Tracks the proposed anti-inflammatory benefit, which is entirely speculative and therefore worth measuring rather than assuming |
| Glycated haemoglobin | 4.8–5.3% | General metabolic context; serotonergic agents can alter appetite and food choice over a multi-week protocol |
| Thyroid-stimulating hormone with free thyroxine | TSH 0.5–2.0 mIU/L | Untreated thyroid dysfunction mimics both the intended benefits and the anxiety adverse effect, confounding any self-assessment |
| Transthoracic echocardiogram | No valvular regurgitation beyond trivial | Screens the theoretical serotonin 2B receptor valvular pathway, relevant only to frequent dosing sustained beyond a year |
Cadence: Blood pressure and heart rate before and 2 hours after each of the first four doses, then weekly seated blood pressure for the remainder of a block; full laboratory panel repeated at 3 months if dosing continues that long, and thereafter every 6–12 months; echocardiography only where frequent dosing has continued beyond 12 months, then every 12–24 months.